

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

PROPOSED ELECTION OF AN ADDITIONAL EXECUTIVE DIRECTOR AND PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Shanghai Haohai Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) convened a meeting of the board of directors (the “**Board**”) of the Company on 24 April 2026 which considered and approved, among other things, the resolutions to nominate Ms. Tian Min as a candidate for the executive director of the Company (“**Executive Director**”), and to nominate Mr. Chan Sui Yu, Mr. Song Yuanyang and Ms. Xu Duoqi as candidates for independent non-executive directors of the Company (“**INEDs**”), respectively. The term of office of each of the said candidates shall commence from the date of approval by the shareholders of the Company (the “**Shareholders**”) at 2025 annual shareholders’ meeting of the Company (the “**AGM**”) until the conclusion of the term of office of the Sixth Session of the Board.

PROPOSED ELECTION OF AN ADDITIONAL EXECUTIVE DIRECTOR

To further enhance the Company’s corporate governance, promote the diversity of the Board, and drive high-quality development, the Board proposes to elect an additional Executive Director, namely Ms. Tian Min (“**Ms. Tian**”). The biographical details of Ms. Tian are set out below:

Ms. Tian Min (田敏), aged 36, currently serves as the secretary of the Board and the joint company secretary of the Company. She joined the Group in July 2015, was working in the Board office, and was appointed as the Company’s securities affairs representative in August 2019. She has also served as the secretary of the Board since December 2019, and as the joint company secretary of the Company since January 2020. She has been a director of OHMK (Tian Jin) Medical Technology Co., Ltd., a subsidiary of the Company, since April 2021, a supervisor of Shanghai Haoleyuan Biotechnology Co., Ltd., a subsidiary of the Company, since November 2022, and has served as a director of Shanghai Haohai Xinchun Medical Biotechnology Co., Ltd., a subsidiary of the Company, since September 2025. She has obtained the “People’s Republic of China Legal Professional Qualification Certificate” issued by the Ministry of Justice of the PRC in March 2014, and obtained the qualification certificate of the secretary of the board of directors issued by the Shanghai Stock Exchange (the “**SSE**”) in July 2019. Ms. Tian obtained a master’s degree in law from East China University of Political Science and Law in July 2015.

Save as disclosed above, as at the date of this announcement, Ms. Tian (i) does not hold any other positions in any member companies of the Group, nor any other major appointments or professional qualifications; (ii) did not hold any directorships in any public company listed in Hong Kong or any other major stock exchanges during the past three years; and (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company. As at the date of this announcement, Ms. Tian holds 10,189 A shares of the Company. Save as disclosed herein, Ms. Tian does not hold any interest in the shares, underlying shares or debentures of the Company and its associated corporations which is required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters relating to the election of Ms. Tian as an Executive Director that need to be brought to the attention of the Shareholders or are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”).

PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

According to the Measures for the Administration of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》) promulgated by the China Securities Regulatory Commission, the consecutive term of office of an independent director of the listed companies should not exceed six years. Mr. Jiang Zhihong (“**Mr. Jiang**”), Mr. Su Zhi (“**Mr. Su**”) and Mr. Yang Yushe (“**Mr. Yang**”) will complete six consecutive years as INEDs in June 2026. Accordingly, Mr. Jiang has tendered his resignation as an INED, chairman of the Nomination Committee, members of the Audit Committee and the Remuneration and Appraisal Committee; Mr. Su has tendered his resignation as an INED, chairman of the Remuneration and Appraisal Committee, members of the Audit Committee and the Nomination Committee; Mr. Yang has tendered his resignation as an INED, members of the Audit Committee and the Strategy and Sustainable Development Committee.

The Board is pleased to announce that it has respectively nominated Mr. Chan Sui Yu, Mr. Song Yuanyang and Ms. Xu Duoqi as INED candidates to fill the vacancies led by the resignations of Mr. Jiang, Mr. Su and Mr. Yang as INEDs.

The biographical details of INED candidates are set out below:

Mr. Chan Sui Yu (“**Mr. Chan**”), aged 59, currently serves as a senior advisor at PwC Asset Appraisal (Shanghai) Co., Ltd. He is a member of the Hong Kong Institute of Certified Public Accountants (HKICPA), a fellow of the Association of Chartered Certified Accountants (FCCA), a fellow of the Royal Institution of Chartered Surveyors (FRICS), and a Chinese Certified Public Valuer (CPV). He currently serves as a council member of the 6th Council of the Chinese Appraisal Society and chairman of its Institutional Governance Committee. Concurrently, he is a standing council member of the 5th Council of the Shanghai Appraisal Society and chairman of its Institutional Governance Committee. He also serves as an adjunct professor or external supervisor for the master of asset appraisal programs at several prestigious universities, including Shanghai University of Finance and Economics, Fudan University, Dongbei University of Finance and Economics, and Zhongnan University of Economics and Law. In recent years, his research has focused on investment and financing for technology innovation enterprises, international and domestic intangible asset valuation, sustainability (ESG), carbon assets, and data assets. Mr. Chan has served at PwC Zhong Tian LLP (Special General Partnership) and its predecessor from July 2002 to June 2025, during which period he was seconded to PwC Asset Appraisal (Shanghai) Co., Ltd. and its predecessor, where he last served as a partner and chief valuer. He graduated from the Chinese University of Hong Kong in June 1989 and holds a Bachelor of Business Administration (First Class Honours).

Mr. Song Yuanyang (“**Mr. Song**”), aged 43, has been on the faculty of East China University of Science and Technology (“**ECUST**”) since July 2012. He currently serves as a professor and doctoral supervisor at ECUST, having previously held the positions of Vice Dean of the School of Business and Head of the Department of Business Administration. His primary research areas encompass corporate strategic management and international business. He was selected for the Shanghai Oriental Talent Program in 2024 and received the Shanghai May Fourth Medal for Youth in 2022. Mr. Song obtained his Ph.D. in management from Fudan University in July 2012.

Ms. Xu Duoqi (“**Ms. Xu**”), aged 51, currently serves as a professor and doctoral supervisor at the Law School of Fudan University. She concurrently holds the positions of director of the Research Center for Digital Economy Rule of Law and director of the Key Laboratory of Smart Rule of Law at Fudan University, as well as an adjunct professor at the Shanghai Advanced Institute of Finance at Shanghai Jiao Tong University. From August 2003 to November 2018, Ms. Xu held various positions at the KoGuan Law School of Shanghai Jiao Tong University, progressing from lecturer to associate professor, professor, and doctoral supervisor. During this period, she also served as a senior Fulbright scholar at Harvard Law School in the United States, a “Hauser” Global Fellow at New York University School of Law, and a senior visiting scholar at other top-tier international law schools, including Duke Law School. She currently serves as an independent director of CMST Development Co., Ltd. (a company listed on the SSE, stock code: 600787) since October 2022, an independent director of Oriental Pearl Group Co., Ltd. (a company listed on the SSE, stock code: 600637) since December 2025. And she also serves as an independent director of Bank of Guilin Co., Ltd. since August 2022, an independent director of Hwabao WP Fund Management Co., Ltd. since March 2024, an independent director of XPHOR Ltd. since December 2025, an external supervisor of Shenneng Property & Casualty Insurance Company Limited since August 2025, and an external supervisor of Aegon THTF Life Insurance Company Limited since March 2026. Ms. Xu graduated from Wuhan University in June 2003, obtaining a doctorate degree in law.

Save as disclosed above, as at the date of this announcement, each INED candidate (i) does not hold any other positions in any member companies of the Group, nor any other major appointments or professional qualifications; (ii) did not hold any directorships in any public company listed in Hong Kong or any other major stock exchanges during the past three years; (iii) does not have any relationship with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iv) does not hold any interest in the shares, underlying shares or debentures of the Company and its associated corporations which is required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) has no other matters relating to the proposed election of INEDs that need to be brought to the attention of the Shareholders or are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

Each INED candidate has confirmed the independence pursuant to Rule 3.13 of the Hong Kong Listing Rules. The Board is also of the opinion that Mr. Chan, Mr. Song and Ms. Xu have complied with the independence guidelines set out in the Hong Kong Listing Rules and they are considered independent thereunder.

CIRCULAR

A circular containing, among other things, the details of the resolutions to elect Ms. Tian as an Executive Director and elect Mr. Chan, Mr. Song and Ms. Xu as INEDs, will be dispatched to the Shareholders as soon as practicable, for their consideration and, if thought fit, approval at the AGM.

The proposed election of Ms. Tian as an Executive Director and election of Mr. Chan, Mr. Song and Ms. Xu as INEDs are subject to the approval of the Shareholders at the AGM. In the event that the above-mentioned proposals are approved by the Shareholders, the Company will enter into a service contract with Ms. Tian, Mr. Chan, Mr. Song and Mr. Xu, respectively, and their terms of office will commence from the date of the approval by Shareholders at the AGM until the conclusion of the term of office of the Sixth Session of the Board. Their respective remuneration will be determined in accordance with the Company's remuneration plan of directors for 2026 to be submitted to Shareholders for consideration and approval at the AGM, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time.

Mr. Jiang, Mr. Su and Mr. Yang have confirmed that they do not have any disagreement with the Board and there are no other matters related to their resignations that are required to be brought to the attention of the Shareholders and The Stock Exchange of Hong Kong Limited. Mr. Jiang, Mr. Su and Mr. Yang shall continue to assume their duties obligations until the election of new INEDs takes effect.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 24 April 2026

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie, Mr. Huang Ming and Mr. Wei Changzheng; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe.

* *For identification purpose only*